Advertisement

U.S. markets open in 1 hour 29 minutes

S&P Futures
4,558.00
+2.00(+0.04%)
Dow Futures
36,056.00
-56.00(-0.16%)
Nasdaq Futures
15,851.25
+36.00(+0.23%)
Russell 2000 Futures
1,849.30
-5.50(-0.30%)
Crude Oil
69.89
+0.51(+0.74%)
Gold
2,049.10
+1.20(+0.06%)

Advertisement

Dr. Reddy's Laboratories Limited (RDY)

NYSE - NYSE Delayed Price. Currency in USD

Visitors trend2W10W9M

69.43

-0.33

(-0.47%)

At close: 04:00PM EST

69.00

-0.43

(-0.62%)

Pre-Market:

07:35AM EST

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Williams %R

View all chart patterns

Performance Outlook

Previous Close	69.76
Open	69.27
Bid	68.83 x 800
Ask	70.52 x 800
Day's Range	69.03 - 69.74
52 Week Range	51.11 - 73.17
Volume	810,771
Avg. Volume	254,552

Market Cap	11.56B
Beta (5Y Monthly)	0.37
PE Ratio (TTM)	18.92
EPS (TTM)	3.67
Earnings Date	N/A
Forward Dividend & Yield	0.49 (0.70%)
Ex-Dividend Date	Jul 07, 2023
1y Target Est	70.61

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

-19% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for RDY

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Dr. Reddy's Laboratories Ltd
Analyst Report: Dr. Reddy's Laboratories LimitedDr. Reddy’s is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (22% of its generics sales), Russia (12%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy’s also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy’s has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy’s also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
Rating
Fair Value
Economic Moat
last monthMorningstar